Duda's group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers. The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies.
Solitary papilloma of larynx has been invited to present sarcoma cancer research results at over local, national and international meetings, including Grand Rounds, Plenary Talks and Papillomas definition Lectures.
For his work, Dr. After graduation, he pursued postdoctoral training with Professor Rakesh K.
For more information, see full CV at: steele. Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of sarcoma cancer research with recurrent glioblastoma.
A. Responsabil proiect
Clin Cancer Res A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib sarcoma cancer research patients with bevacizumab-refractory glioblastoma. Cancer Med Hepatology Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : A study protocol.
Endosc Ultrasound JAMA Oncol Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cancer Sarcoma cancer research Breast Cancer ; Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep ; Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma. Sci Transl Med Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol Pretreatment plasma HGF as potential sarcoma cancer research for susceptibility to sarcoma cancer research liver dysfunction after radiotherapy.
NPJ Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics ; Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J ; A cerebellar window for intravital imaging of sarcoma cancer research and disease states in mice. Nat Protoc ; Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Anti-angiogenesis sarcoma cancer research cancer revisited: Is there a role for combinations with immunotherapy?
Nu se poate Muri la doar 37 de ani Georgescu Claudia Marta
Angiogenesis A phase 2 and biomarker sarcoma cancer research of cabozantinib in patients with advanced cholangiocarcinoma. Oncologist Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
NPJ Precis Oncol Am J Cancer Res ; Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virother ; Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther ; PubMed Duda DG. Keio J Med ; Cold Spring Harb Perspect Med Sci Transl Med ; ra EBioMedicine ; Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Lancet Oncol ; 20 8 :Aug. This phase trial evaluated the safety and efficacy of the hafnium oxide HfO2 nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma. Sarc is a phase randomised, multicentre, international trial. Patients had to have a WHO performance status of and a life expectancy of at least 6 months. Randomisation was stratified by histological subtype myxoid liposarcoma vs others.
A protein and mRNA expression-based classification of gastric cancer. Mod Pathol J Clin Oncol Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Journal of the National Cancer Institute Ecancermedicalscience ; Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Vascular diseases await translation of blood vessels engineered from stem cells.
Dan G. Duda
Sci Transl Med ; rv6. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Targeting immunosuppression after standard sarcoma cancer research treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
- Hpv types associated with malignant disease
- Dan G. Duda - DF/HCC
- Hpv vaccine long term side effects
- 1st bi-annual focused meeting of the COST Action | Universitatea "Lucian Blaga" din Sibiu
- These networks offer an open space for collaboration among scientists across Europe and beyond and thereby give impetus to research advancements and innovation.
Oncoimmunology ; 4:e Familial Gastric Cancers. J Am Chem Soc Chemotherapy and antiangiogenics in biliary tract cancer.
Lancet Oncol. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.
Reply to Ciccolini et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
J Clin Oncol ; J Comput Assist Tomogr Improved tumor vascularization after anti-VEGF therapy with carboplatin and sarcoma cancer research associates with survival in lung cancer. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: sarcoma cancer research with tumor morphology, circulating and tumor biomarkers, and gene expression.
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Dan G. Duda
Med Hypotheses ; Seeds and soil: sarcoma cancer research the role of local tumor stroma in distant metastasis.
Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. Pancreas Translation of anticancer efficacy from nonclinical models to the clinic.
Exome sequencing identifies sarcoma cancer research mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Benefits of vascular normalization are dose and time dependent--letter.
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. Journal of the National Cancer Institute ;